CLINICAL ROLE -
Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.
FCRL5-Directed CAR T-Cell Therapy: A Novel Therapeutic Approach for Multiple Myeloma
Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma
New, Emerging Treatment Options for Patients With Multiple Myeloma
FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma
Venetoclax With 5-Azacytidine Effective in Treating Patients With Multiple Myeloma
Addressing the Challenges of Implementing Bispecific Antibodies in Health Care Centers